http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2155096-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_621f0ea7dc150d921dbc4265f5fa1ab8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_977ebb660999f345084ffad260515ff6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 1994-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b01cfd6a512f8a049b02cbe61941858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_277b9eb4d6c93c669461f286d17c1e90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef8bc704ffbbcc5dbf9a3aa019b3b17b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b84cdd93836f33d2533ede59603857ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e74483a743ff1ccf1b125d7f2c07714b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f498208b666d022c9a691ffc65ddb23 |
| publicationDate | 1995-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2155096-A1 |
| titleOfInvention | 2,2'-bi-1h-pyrrole derivates with immunomodulating activity |
| abstract | New and known 5-[(2H-pyrrol-2-ylidene)methyl]-2,2'-bi-1H-pyrrole derivatives, having immunomodulating activity and, represented by general formula (I) wherein, subject to a proviso, R1 represents hydrogen, phenyl, C1-C20 alkyl or C2-C20 alkenyl, wherein the alkyl and alkenyl groups may be unsubstituted or substituted by 1 to 3 substituents chosen independently from halogen, C1-C6 alkoxy, hydroxy, aryl and aryloxy; R2 represents hydrogen, C1-C6 alkyl, cyano, carboxy or (C1-C6 alkoxy)carbonyl; R3 represents halogen, hydroxy or C1-C11 alkoxy unsubstituted or substituted by phenyl; R4 represents hydrogen, C1-C6 alkyl or phenyl; each or R5 and R6 independently represents hydrogen, C2-C20 alkanoyl, C3-C20 alkenoyl, phenyl, C1-C20 alkyl or C2-C20 alkenyl, wherein the alkanoyl, alkenoyl, alkyl and the alkenyl groups may be unsubstituted or substituted by 1 to 3 substituents chosen independently from halogen, C1-C6 alkoxy, hydroxy, aryl, aryloxy, cyano, carboxy, (C1-C6 alkoxy)carbonyl, (C3-C4 alkenyl)carbamoyl, aralkylcarbamoyl, arylcarbamoyl and -CONRcRd in which each of Rc and Rd independently is hydrogen or C1-C6 alkyl or Rc and Rd, taken together with the nitrogen atom to which they are linked, form a morpholino or piperidino ring; or two of R4, R5 and R6 taken together form a C4-C12 polymethylene chain, which can be unsubstituted or substituted by a C1-C12 alkyl, by a C2-C12 alkenyl or by a C1-C12 alkylidene group, wherein the alkyl, alkenyl and alkylidene groups may be in turn unsubstituted or substituted by a substituent chosen from halogen, C1-C6 alkoxy, hydroxy, cyano, carboxy, (C1-C6 alkoxy)carbonyl, aryloxy and aryl; the remaining one being hydrogen or C1-C12 alkyl; and the pharmaceutically acceptable salts thereof, are disclosed. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7144912-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7491745-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6407244-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6602879-B2 |
| priorityDate | 1993-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 254.